Simcere Pharmaceutical Group (HKSE:02096) EBIT per Share : HK$0.32 (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group EBIT per Share?

Simcere Pharmaceutical Group's EBIT per Share for the six months ended in Dec. 2023 was HK$-0.66. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.32.

During the past 12 months, the average EBIT per Share Growth Rate of Simcere Pharmaceutical Group was 24.50% per year. During the past 3 years, the average EBIT per Share Growth Rate was 4.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was -10.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Simcere Pharmaceutical Group's EBIT per Share or its related term are showing as below:

HKSE:02096' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -33.2 Med: -13.05 Max: 4.4
Current: 4.4

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Simcere Pharmaceutical Group was 4.40% per year. The lowest was -33.20% per year. And the median was -13.05% per year.

HKSE:02096's 3-Year EBIT Growth Rate is ranked worse than
55.62% of 863 companies
in the Drug Manufacturers industry
Industry Median: 7.3 vs HKSE:02096: 4.40

Simcere Pharmaceutical Group's EBIT for the six months ended in Dec. 2023 was HK$-1,716 Mil.

Simcere Pharmaceutical Group EBIT per Share Historical Data

The historical data trend for Simcere Pharmaceutical Group's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group EBIT per Share Chart

Simcere Pharmaceutical Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.51

0.43

0.69

0.39

0.33

Simcere Pharmaceutical Group Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial							0.42	0.03	0.36	0.98	-0.66

Simcere Pharmaceutical Group EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Simcere Pharmaceutical Group's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	847.248	/	2608.534
=	0.32

Simcere Pharmaceutical Group's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1715.846	/	2598.118
=	-0.66

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.32

Simcere Pharmaceutical Group (HKSE:02096) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Simcere Pharmaceutical Group EBIT per Share Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Simcere Pharmaceutical Group (HKSE:02096) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » EBIT per Share

Traded in Other Exchanges

S2P:Germany

Address

No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042

Website

https://www.simcere.com

Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Executives

Wang Xi	2305 Beneficiary of a trust
Ren Jinsheng	2202 Interest of your spouse
Right Wealth Holdings Limited	2501 Other
Wang Xi	2501 Other
Simcere Investments Group Limited	2501 Other
Excel Investments Group Limited	2501 Other
Simcere Pharmaceutical Holding Limited	2501 Other
Simcere Holding Limited	2501 Other
Artking Global Limited	2501 Other
Ren Zhen	2501 Other
Ren Yong	2501 Other
Ren Weidong	2501 Other
Peng Suqin	2501 Other
P&h Holdings Group Ltd.	2501 Other
Li Shimeng	2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines